Quarterly report pursuant to Section 13 or 15(d)

Acquisition of Emerald Health Therapeutics, Inc. - Fair Value Allocation of Preliminary Purchase Price (Details)

v3.22.2.2
Acquisition of Emerald Health Therapeutics, Inc. - Fair Value Allocation of Preliminary Purchase Price (Details) - Emerald Health Therapeutics, Inc. - USD ($)
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2022
Purchase Consideration    
Common stock $ 10,823,033  
Stock options issued 114,249  
Warrants issued 314,498  
Transaction costs 1,604,444 $ 1,604,444
Total consideration 12,856,224  
Assets acquired    
Cash and cash equivalents 8,177,488  
Accounts receivable 579,139  
Property, plant and equipment 223  
Current assets held for sale (property, plant and equipment) 7,254,576  
Accounts payable (927,222)  
Accrued payroll liabilities (459,525)  
Other current liabilities (1,380,526)  
Insurance Payable (378,905)  
Accounts payable - related parties (9,024)  
Total net assets acquired $ 12,856,224